FINWIRES · TerminalLIVE
FINWIRES

Cantor Fitzgerald Initiates Silence Therapeutics at Overweight

By

Silence Therapeutics (SLN) has an average rating of overweight and mean price target of $31.20, according to analysts polled by FactSet.

What else is happening in Research?